^(90)Y标记单克隆抗体CD45的研究

Labeling of CDTPA-dianhydride-coupled CD45 monoclonal antibody with yttrium-90

目的制备90Y标记的CD45单克隆抗体,为用90Y-CDTPA-CD45mAb治疗急性白血病奠定基础。方法利用环酐DTPA为络合剂,螯合90Y与CD45mAb,并对90Y-CDTPA-CD45mAb的标记率、放化纯度、稳定性、比活度、免疫活性进行检测。结果在CDTPA与IgG的最佳摩尔比为20∶1的条件下,90Y-CDTPA-CD45mAb的标记率为95%,放化纯度达99.8%,稳定性良好,比活度为1.9mCi/mg,免疫活性与未标记的CD45mAb相比无明显差异。结论90Y-CDTPA-CD45mAb是一个较理想的靶向治疗制剂,可以用于下一步的急性白血病治疗研究。

Objective To explore the methods for labeling CDTPA-coupled CD45 monoclonal antibody （mAb） with yttrium-90 （^90Y） for potential acute myeloid therapy. Methods CD45 mAb was labeled with ^90Y by CDTPA and the labeling rate, radiochemical purity, final specific activity, and immunological activity of the mAb were detected, Results With the optimal molar ratio of CDTPA/Ab at 20：1, the labeling rate was 95%, radiochemical purity 99.8%, and final specific activity 1.9 mCi/mg. This conjugate was stable in vitro with comparable immunological activity in comparison with unlabeled CD45 mAb. Conclusion ^90Y-CDTPA-CD45 mAb possesses good properties as an ideal targerting therapeutic agent for acute leukemia.